BioNTech SE American Depositary Share - BNTX STOCK NEWS

BioNTech has successfully acquired Kite's solid tumor neoantigen T cell receptor (TCR) R&D platform and clinical manufacturing facility in Gaithersburg, MD, enhancing its capabilities in individualized cancer therapies. This transaction, announced on July 19, 2021, marks a pivotal move in BioNTech's strategy to complement its growth through targeted acquisitions, following the acquisition of Neon Therapeutics in 2020. The integration of Kite's assets is expected to accelerate BioNTech's cell therapy pipeline and expand its North American operations.

BioNTech SE (BNTX) has completed the acquisition of Kite's solid tumor neoantigen T cell receptor (TCR) R&D platform and clinical manufacturing assets in Gaithersburg, MD. This strategic move enhances BioNTech's cell therapy pipeline and manufacturing capabilities in North America, following its acquisition of Neon Therapeutics in 2020. The deal, which was announced on July 19, 2021, aligns with BioNTech’s strategy of accelerating development through targeted acquisitions. All Kite employees at the facility were offered jobs with BioNTech, ensuring operational continuity.

BioNTech (BNTX) will release its financial results for Q2 2021 on August 9, 2021. Investors are invited to join a conference call and webcast at 8:00 a.m. EDT. The event will include a corporate update alongside the financial results, reflecting the company's ongoing developments in immunotherapy and mRNA vaccines. Participants can access presentation slides and audio via BioNTech's investor relations page. The company emphasizes its innovative approach to cancer and serious diseases through a broad portfolio of therapies.

BioNTech has launched a project to develop the first mRNA-based vaccine for Malaria, with clinical trials set to start by the end of 2022. This initiative aims to create effective vaccine candidates targeting known Malaria antigens and to establish sustainable production capabilities in Africa. Supported by WHO and Africa CDC, the project aligns with the ‘eradicateMalaria’ initiative of the kENUP Foundation. BioNTech is leveraging its extensive mRNA research background, building on successful COVID-19 vaccine efforts with Pfizer.

The kENUP Foundation, in collaboration with various global health organizations, is addressing the significant infectious disease burden in Africa. A major event titled Fighting Infectious Diseases – Focus on Africa is scheduled for July 26 from 16:00-17:30 CEST, featuring prominent speakers from WHO, Africa CDC, BioNTech, and the European Commission. The event aims to share sustainable solutions for combating diseases on the continent and will be live-streamed, allowing global participation, including a media Q&A session.

On July 23, 2021, Pfizer and BioNTech announced a U.S. government purchase of an additional 200 million doses of their COVID-19 vaccine, increasing total doses to 500 million. Deliveries are scheduled between October 2021 and April 2022, with 110 million expected by year-end. The vaccine, utilizing BioNTech's mRNA technology, is authorized for emergency use but not yet fully approved by the FDA. The companies aim to provide free vaccines to U.S. residents and support global vaccination efforts for low-income nations.

Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX) announced the U.S. government's purchase of an additional 200 million doses of their COVID-19 vaccine. This increases the total to 500 million doses under their supply agreement. The companies plan to deliver 110 million doses by December 31, 2021, and the remaining doses by April 30, 2022. The U.S. government will continue to provide the vaccine for free. The vaccine remains under Emergency Use Authorization and is aimed at preventing COVID-19.

Pfizer and BioNTech have signed a letter of intent with The Biovac Institute to manufacture and distribute their COVID-19 vaccine in Africa. This partnership aims to enhance vaccine access within the African Union, with production expected to exceed 100 million doses annually once fully operational. Technical transfer and equipment installations are set to begin immediately, with finished dose manufacturing commencing in 2022. Both companies continue to prioritize equitable vaccine distribution globally, committing to provide 2 billion doses to low and middle-income countries in 2021 and 2022.

Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX) have signed a letter of intent with The Biovac Institute to manufacture and distribute the Pfizer-BioNTech COVID-19 Vaccine in Africa. Biovac will join Pfizer's global supply chain, enhancing production capabilities across three continents with over 20 facilities. Production is set to begin in 2022, aiming for more than 100 million doses annually for the African Union. This collaboration underscores Pfizer's commitment to equitable vaccine access and explores further partnerships in Latin America.